Evidence map›Paper›PMID 30216294›Full record

Trial reportThe Pediatric infectious disease journal2018

Congenital Cytomegalovirus and HIV Perinatal Transmission.

Kristina Adachi, Jiahong Xu, Bonnie Ank, D Heather Watts, Margaret Camarca, Lynne M Mofenson, Jose Henrique Pilotto, Esau Joao, Glenda Gray, Gerhard Theron and 15 more

Open access · greenAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The Pediatric infectious disease journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. [Congenital cytomegalovirus infection, is more prevalent in our country in newborns exposed to HIV?]Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022
    Article
  10. Article
  11. Review
  12. Article
  13. Overview of Human Cytomegalovirus Pathogenesis.Methods in molecular biology (Clifton, N.J.) · 2021
    Review
  14. Review
  15. Article
  16. Article
  17. The impact of maternal HIV and malaria infection on the prevalence of congenital cytomegalovirus infection in Western Kenya.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2019
    Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 16 institutions in 4 countries.

Kristina AdachiFrom the David Geffen UCLA School of Medicine, Los Angeles, CA.
Jiahong XuWestat, Rockville, MD.
Bonnie AnkFrom the David Geffen UCLA School of Medicine, Los Angeles, CA.
D Heather WattsOffice of the Global AIDS Coordinator, U.S. Department of State, Washington, DC.
Margaret CamarcaWestat, Rockville, MD.
Lynne M MofensonEunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD.
Jose Henrique PilottoHospital Geral de Nova Iguaçu, Nova Iguaçu, RJ, Brazil.
Esau JoaoHospital Federal dos Servidores do Estado, Rio de Janeiro, RJ, Brazil.
Glenda GraySAMRC and Perinatal HIV Research Unit, University of Witwatersrand, Cape Town, South Africa.
Gerhard TheronStellenbosch University/Tygerberg Hospital, Cape Town, South Africa.
Breno SantosHospital Conceicao, Porto Alegre, RS, BrazilHospital Femina, Porto Alegre, RS, Brazil.
Rosana Fonseca
Regis KreitchmannIrmandade da Santa Casa de Misericordia de Porto Alegre, RS, Brazil.
Jorge PintoFederal University of Minas Gerais, Belo Horizonte, MG, Brazil.
Marisa M Mussi-PinhataRibeirão Preto Medical School, University of São Paulo, SP, Brazil.
Daisy Maria MachadoEscola Paulista de Medicina-Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Mariana CeriottoFoundation for Maternal and Infant Health (FUNDASAMIN), Buenos Aires, Argentina.
Mariza G MorgadoFundacao Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, RJ, Brazil.
Yvonne J BrysonFrom the David Geffen UCLA School of Medicine, Los Angeles, CA.
Valdilea G VelosoFundacao Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, RJ, Brazil.
Beatriz GrinsztejnFundacao Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, RJ, Brazil.
Mark MirochnickBoston University School of Medicine, Boston, MA.
Jack MoyeEunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD.
Karin Nielsen-SainesFrom the David Geffen UCLA School of Medicine, Los Angeles, CA.
MPH for the NICHD HPTN 040 Study Team
University of California, Los Angeles · USFundação Oswaldo Cruz · BRIrmandade da Santa Casa de Misericórdia de São Paulo · BRWestat (United States) · USBoston University · USEunice Kennedy Shriver National Institute of Child Health and Human Development · USHospital Federal dos Servidores do Estado · BRHospital Nossa Senhora da Conceição · BRInfant Foundation · ARNational Institutes of Health · USSouth African Medical Research Council · ZATygerberg Hospital · ZAUnited States Department of State · USUniversidade de São Paulo · BRUniversidade Federal de São Paulo · BRUniversidade Iguaçu · BR

Funding

LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Jennifer Jao, Sharon A Nachman · 2011 to 2026
$278.1M
Statistical and Data Management Center-Pediatric,Adolescent, and Maternal CTGUM1AI068616 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Sean Scott Brummel, Marlene Ann Cooper · 2011 to 2026
$155.6M
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) GroupU01AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI JACKSON, J BROOKS · 2006 to 2010
$109.7M
UCLA AIDS Prevention and Treatment Clinical Trials UnitUM1AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Judith S. Currier, RAPHAEL J LANDOVITZ · 2012 to 2026
$51.8M
LC - IMPAACT Leadership GroupUM1AI106716 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$47.2M
Soweto Clinical Trials UnitUM1AI069453 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI Glenda E Gray, Lerato Mohapi · 2012 to 2026
$40.9M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KITCHEN, SCOTT G · 1991 to 2018
$39.9M
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)UM1AI069476 · NIAID · FUNDACAO OSWALDO CRUZ · PI BEATRIZ GRINSZTEJN · 2012 to 2026
$26.3M
UCLA AIDS Prevention and Treatment Clinical Trials UnitU01AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CURRIER, JUDITH S. · 2007 to 2011
$13.9M
BRAZILIAN AIDS PREVENTION TRIALS INTERNATIONAL NETWORKU01AI047986 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BRYSON, YVONNE J · 2000 to 2006
$13.3M
NIAID NIH HHS P30 AI028697NIAID NIH HHS U01 AI047986NIAID NIH HHS U01 AI068632NIAID NIH HHS U01 AI069424NIAID NIH HHS UM1 AI068616NIAID NIH HHS UM1 AI068632NIAID NIH HHS UM1 AI069424NIAID NIH HHS UM1 AI069453NIAID NIH HHS UM1 AI069476NIAID NIH HHS UM1 AI106716NIDDK NIH HHS HHSN267200800001C
6 · The paper itself

Abstract

backgroundCongenital cytomegalovirus (CMV) infection (cCMV) is an important cause of hearing loss and cognitive impairment. Prior studies suggest that HIV-exposed children are at higher risk of acquiring cCMV. We assessed the presence, magnitude and risk factors associated with cCMV among infants born to HIV-infected women, who were not receiving antiretrovirals during pregnancy.

methodscCMV and urinary CMV load were determined in a cohort of infants born to HIV-infected women not receiving antiretrovirals during pregnancy. Neonatal urines obtained at birth were tested for CMV DNA by qualitative and reflex quantitative real-time polymerase chain reaction.

resultsUrine specimens were available for 992 (58.9%) of 1684 infants; 64 (6.5%) were CMV-positive. Mean CMV load (VL) was 470,276 copies/ml (range: < 200-2,000,000 copies/ml). Among 89 HIV-infected infants, 16 (18%) had cCMV versus 42 (4.9%) of 858 HIV-exposed, uninfected infants (P < 0.0001). cCMV was present in 23.2% of infants with in utero and 9.1% infants with intrapartum HIV infection (P < 0.0001). Rates of cCMV among HIV-infected infants were 4-fold greater (adjusted OR, 4.4; 95% CI: 2.3-8.2) and 6-fold greater among HIV in utero-infected infants (adjusted OR, 6; 95% CI: 3-12.1) compared with HIV-exposed, uninfected infants. cCMV was not associated with mode of delivery, gestational age, Apgar scores, 6-month infant mortality, maternal age, race/ethnicity, HIV viral load or CD4 count. Primary cCMV risk factors included infant HIV-infection, particularly in utero infection.

conclusionHigh rates of cCMV with high urinary CMV VL were observed in HIV-exposed infants. In utero HIV infection appears to be a major risk factor for cCMV in infants whose mothers have not received combination antiretroviral therapy in pregnancy.

Indexed as

Infectious Disease Transmission, VerticalAnti-Retroviral AgentsCohort StudiesCytomegalovirusCytomegalovirus InfectionsDNA, ViralFemaleHIV InfectionsHumansInfantInfant, NewbornPregnancyPregnancy Complications, InfectiousReal-Time Polymerase Chain ReactionRisk FactorsViral LoadAnti-Retroviral AgentsDNA, Viral

Identifiers

PMID30216294
PMCPMC6129438
OpenAlexW2894915092

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.